Gilead response to NICE questions 8th April 2015 - supplementary data and analyses

3 c) The data in Table 1 below is provided to support 12 weeks duration in line with the feedback from the European clinical experts regarding the stratification of risk of clinical disease progression. These data show that in treatment experienced patients with cirrhosis and platelets ≥75,000 mm^3 a 12 week duration results in similar efficacy to 24 week duration.

Table 1: SVR12 rates observed in treatment experienced patients with cirrhosis stratified by platelet count

	12 weeks LDV/SOF±RBV	**24 weeks LDV/SOF±RBV**
Platelets <75,000 mm^3	79% (19/24)	100% (4/4)
Platelets ≥75,000 mm^3	96% (197/206)	98% (116/118)

A cost-effectiveness analysis was run based on the SVR12 data for patients with platelets ≥75,000 mm^3 (96%; 197/206), to provide the ICER for patients a low risk clinical disease progression and with subsequent retreatment options. The ICERs are presented using transitions based on both Cardoso et al and Fattovich et al, which assess the impact of a slower transition from compensated cirrhosis to decompensated cirrhosis (i.e. for patients defined at lower risk of clinical disease progression). Given the similarity in the resulting ICERs for the treatment experienced population with cirrhosis, this cost-effectiveness is not sensitive to changes in the assumptions on risk of clinical disease progression.

Table 1: Cost-effectiveness results for 12 weeks LDV/SOF in GT1 or GT4 treatment experienced patients with compensated cirrhosis who are at low risk of clinical disease progression and have subsequent retreatment options

Technologies	**Cardoso**			**Technologies**	**Fattovich**		
	QALYs	**Costs**	**ICER**		**QALYs**	**Costs**	**ICER**
LDV/SOF	9.61	£60,378	£4,460	LDV/SOF	9.74	£61,650	£4,602
SOF+SMV	9.49	£79,754	Dominated	SOF+SMV	9.67	£81,284	Dominated
SOF+PR	8.59	£63,193	Dominated	SOF+PR	9.19	£66,473	Dominated
SMV+PR	8.31	£62,046	Dominated	SMV+PR	9.03	£65,804	Dominated
TVR+PR	7.46	£63,325	Dominated	TVR+PR	8.59	£68,855	Dominated
BOC+PR	6.95	£68,413	Dominated	BOC+PR	8.33	£74,964	Dominated
PR	5.74	£47,441	ED	PR	7.68	£56,386	ED
No treatment	5.19	£40,651	-	No treatment	7.38	£50,797	